A Harm ReductionApproach to Addressing the HIV,STIs,and Substance UseSyndemicamong People Engaging in SexWork in Alabama
Project Number3P30AI027767-35S1
Former Number5P30AI027767-34
Contact PI/Project LeaderHEFFRON, RENEE A.
Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
PROJECT SUMMARY
Despite the availability of biomedical prevention tools to end the HIV epidemic, incidence of HIV and other STIs
in Alabama remain high, while uptake of prevention such as PrEP remains low. Further, opioid prescribing,
use, and overdose-related death are also disproportionately high in Alabama, with an increasing impact on
Black individuals. Converging risk related to HIV,STIs,and drug use can be attributed in part to socioeconomic
inequalities in the Deep South which may drive sexwork. Recent evidence suggests individuals engaged in
sexwork report higher rates of diverse drug useand increased vulnerability to HIV and other STIs compared to
other individuals in Alabama. Sexworkers and people who use drugs represent vulnerable groups who face
unique barriers to HIV prevention including PrEP. However, HIV services for sexworkers in Alabamaare
limited, and no evidence-based interventions in the CDC’s Compendium have been tailored for sexworkers.
Through community-academic partnership, this project will usesyndemic theory to directly address the needs
of a severely underserved population through development of a PrEP intervention for people engaging in sexwork in Alabama. The Specific Aims are to: (1) Develop a harm reduction intervention that responds to
syndemic drug use, HIV,and STIs for people engaged in sexwork, [Year 1] and (2) Pilot and evaluate the
acceptability, appropriateness, and feasibility of the intervention to increase PrEP uptake among people
engaged in sexwork [Year 2]. Within Aim 1, we will leverage existing quantitative data to identify intervenable
Outer Setting characteristics (patient needs and resources) and collect de novo qualitative data to further
characterize sexwork, contextualize the needs and resources of individuals engaged in sexwork, and
characterize the processes and resources of Birmingham AIDS Outreach (BAO) to inform intervention
approaches. Under Aim 2, pending CFAR renewal, we will pilot the intervention at BAO with 40 individuals
engaging in sexwork, and will evaluate the intervention’s acceptability, appropriateness, and feasibility from a
participant and provider perspective. We will assess clinical outcomes and preliminary effects on PrEP useand
uptake of harm reduction strategies (use of condoms and sterile syringes). This work will be guided by the
Consolidated Framework for Implementation Research (CFIR), RE-AIM framework, and ERIC strategies. The
project will result in formation of a Health Equity Research Assembly, development of a novel harm reduction
intervention for people engaged in sexwork, and, if Year 2 is awarded, pilot data to inform a subsequent R-
level proposal.
Public Health Relevance Statement
PROJECT NARRATIVE
The supplement project aims to develop and pilot a PrEP intervention for people engaging in sexwork in
Alabama. The project is grounded in syndemics theory and implementation science frameworks to directly
address the needs of an underserved population through community-academic partnership.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAcquired Immunodeficiency SyndromeAddressAlabamaAwardAwarenessBlack PopulationsCOVID-19 pandemicCessation of lifeCharacteristicsClinicalClinical TrialsCommunitiesConsolidated Framework for Implementation ResearchDataDeep SouthDevelopmentDrug usageDrug userEpidemicEvidence based interventionFaceFoodFundingHIVHIV InfectionsHIV diagnosisHIV/STDHarm ReductionHealthHealth ResourcesHealthcareHepatitis C virusHousingIncidenceIndividualInjecting drug userInterventionInterviewMeasuresMethodsOutcomeOverdoseParticipantPatientsPersonsPharmaceutical PreparationsPopulationPrevalencePreventionProcessProviderQualitative ResearchReach, Effectiveness, Adoption, Implementation, and MaintenanceReportingResearchResourcesRiskRisk ReductionRuralServicesSterilityStructureSurveysSyringesTarget PopulationsTestingUnderserved PopulationUnited StatesVulnerable PopulationsWorkclinical outcome assessmentcondomsevidence basefollow-uphealth equityimplementation frameworkimplementation outcomesinformantinsightnoveloutreachparent grantpre-exposure prophylaxisprescription opioidpreventive interventionresponserisk perceptionrole modelsexsocial stigmasocioeconomic disparitysubstance usesyndemicsystematic reviewtesting accesstheoriestooluptake
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
01-March-1997
Project End Date
31-May-2024
Budget Start Date
01-September-2023
Budget End Date
31-May-2024
Project Funding Information for 2023
Total Funding
$213,601
Direct Costs
$155,523
Indirect Costs
$58,078
Year
Funding IC
FY Total Cost by IC
2023
National Institute of Allergy and Infectious Diseases
$213,601
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3P30AI027767-35S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P30AI027767-35S1
Patents
No Patents information available for 3P30AI027767-35S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P30AI027767-35S1
Clinical Studies
No Clinical Studies information available for 3P30AI027767-35S1
News and More
Related News Releases
No news release information available for 3P30AI027767-35S1
History
No Historical information available for 3P30AI027767-35S1
Similar Projects
No Similar Projects information available for 3P30AI027767-35S1